Short Interest in Franklin Genomic Advancements ETF (BATS:HELX) Declines By 37.8%

Franklin Genomic Advancements ETF (BATS:HELX) was the recipient of a large decline in short interest in July. As of July 31st, there was short interest totaling 2,561 shares, a decline of 37.8% from the July 15th total of 4,118 shares. Approximately 0.6% of the shares of the company are sold short. Based on an average trading volume of 4,032 shares, the short-interest ratio is currently 0.6 days.

Institutional Investors Weigh In On Franklin Genomic Advancements ETF

Institutional investors have recently bought and sold shares of the stock. Kestra Advisory Services LLC bought a new position in Franklin Genomic Advancements ETF in the 4th quarter valued at about $39,000. LPL Financial LLC raised its position in shares of Franklin Genomic Advancements ETF by 22.4% during the 4th quarter. LPL Financial LLC now owns 11,133 shares of the company’s stock worth $404,000 after buying an additional 2,037 shares in the last quarter. Osaic Holdings Inc. raised its position in shares of Franklin Genomic Advancements ETF by 19.1% during the 2nd quarter. Osaic Holdings Inc. now owns 3,132 shares of the company’s stock worth $87,000 after buying an additional 502 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Franklin Genomic Advancements ETF in the 2nd quarter worth approximately $42,000.

Franklin Genomic Advancements ETF Stock Performance

Shares of HELX stock opened at $41.14 on Tuesday. Franklin Genomic Advancements ETF has a 1 year low of $29.26 and a 1 year high of $41.76. The firm has a market capitalization of $16.46 million, a PE ratio of 26.71 and a beta of 1.05. The stock has a fifty day moving average of $39.02 and a two-hundred day moving average of $35.73.

Franklin Genomic Advancements ETF Company Profile

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that is based on the Solactive Genomics index. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is managed by Franklin Templeton.